A vaccine to prevent Klebsiella pneumoniae infections using a multivalent bioconjugate
Official title: A multivalent O-antigen bioconjugate vaccine for the prevention of Klebsiella pneumoniae infections
Funded at Vaxnewmo, LLC · NIH-11412495 · Data updated 2026-11-12
A new vaccine approach aims to protect people from dangerous Klebsiella pneumoniae infections, including drug-resistant strains.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vaxnewmo, LLC NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | July 15, 2022 |
| Project end | July 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $1,000,000 |
| NIH project number | 5R42AI165116-05 |
| Project ID | NIH-11412495 on NIH RePORTER |
Who could benefit from this research
✓Could help
Individuals at risk for Klebsiella infections, including patients in healthcare settings and those with prior antibiotic exposure or immune compromise.
✕Less likely to help
People without exposure risk or those for whom vaccination is not indicated may not benefit.
What this research studies
This project uses a bioconjugation method to create a multivalent vaccine that targets multiple Klebsiella pneumoniae strains. The vaccine is designed to be produced using a lab-based bioconjugation process that links bacterial polysaccharides to a carrier protein. The goal is to prevent infections in people who are at high risk for healthcare- and community-associated illness, including those with compromised immune systems or frequent antibiotic exposure.
Why it matters
Potential benefit: If successful, the vaccine could reduce infections and limit the spread of resistant Klebsiella.
How similar studies have gone: Conjugate vaccines have successfully protected against other bacterial pathogens, suggesting potential for efficacy against Klebsiella.
Where this research is happening
-
Vaxnewmo, LLC
Saint Louis, United States Active
Researchers
- Principal investigator: Harding, Christian — Vaxnewmo, LLC
- Study coordinator: Harding, Christian
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.